Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00784654 · ClinicalTrials.gov registry record · Phase 3
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT00784654 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 276 participants.
The verdict
NCT00784654, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months
Interventions
- DRUG Placebo
- DRUG Lisdexamfetamine dimesylate (LDX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2009-01-27 |
| Est. Completion | 2011-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00784654
The ClinicalTrials.gov registry entry for NCT00784654 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00784654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00784654 about?
NCT00784654 is a clinical study titled "Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17". The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months
What is the current status of trial NCT00784654?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2009-01-27. Estimated completion is 2011-10-26.
What interventions are being tested in trial NCT00784654?
The interventions under investigation include: Placebo (DRUG), Lisdexamfetamine dimesylate (LDX) (DRUG).
Who is sponsoring clinical trial NCT00784654?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.